Faculty Advisor

Heilman, Destin

Faculty Advisor

Mattson, Anita Elaine

Center

UMMC / University of Massachusetts Medical Center

Abstract

HIV Protease Inhibitors (PIs) have become one of the most effective anti-viral drugs on the market. Darunavir (DRV), the most potent FDA-approved PI, has been essential in the fight against HIV/AIDS. However, the ability of the HIV protease to mutate and grow resistance has become a global concern. To address this issue, two new series of PIs were designed using the substrate envelope hypothesis. UMass 1-10 and the mono-/di-hydroxyl series compounds are derived from the DRV backbone, with modifications made on the P1' and P2' sites. The compounds were kinetically tested against resistant mutants and crystal structures were solved. Pico-molar potencies were observed for all compounds. These results can be used to design new PIs with increased efficacy against a wide range of mutants.

Publisher

Worcester Polytechnic Institute

Date Accepted

April 2018

Major

Biochemistry

Project Type

Major Qualifying Project

Accessibility

Unrestricted

Advisor Department

Chemistry and Biochemistry

Share

COinS